Literature DB >> 21858606

Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line.

André Toulouse1, Grace C Collins, Aideen M Sullivan.   

Abstract

The neurotrophin growth/differentiation factor 5 (GDF5) is studied as a potential therapeutic agent for Parkinson's disease as it is believed to play a role in the development and maintenance of the nigrostriatal system. Progress in understanding the effects of GDF5 on dopaminergic neurones has been hindered by the use of mixed cell populations derived from primary cultures or in vivo experiments, making it difficult to differentiate between direct and indirect effects of GDF5 treatment on neurones. In an attempt to establish an useful model to study the direct neuronal influence of GDF5, we have characterised the effects of GDF5 on a human neuronal cell line, SH-SY5Y. Our results show that GDF5 has the capability to promote neuronal but not dopaminergic differentiation. We also show that it promotes neuronal survival in vitro following a 6-hydroxydopamine insult. Our results show that application of GDF5 to SH-SY5Y cultures induces the SMAD pathway which could potentially be implicated in the intracellular transmission of GDF5's neurotrophic effects. Overall, our study shows that the SH-SY5Y neuroblastoma cell line provides an excellent neuronal model to study the neurotrophic effects of GDF5.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21858606     DOI: 10.1007/s12640-011-9266-7

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  42 in total

Review 1.  Signaling inputs converge on nuclear effectors in TGF-beta signaling.

Authors:  P ten Dijke; K Miyazono; C H Heldin
Journal:  Trends Biochem Sci       Date:  2000-02       Impact factor: 13.807

2.  TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells.

Authors:  Cristina Gómez-Santos; Santiago Ambrosio; Francesc Ventura; Isidre Ferrer; Julia Reiriz
Journal:  Brain Res       Date:  2002-12-20       Impact factor: 3.252

Review 3.  Progress in Parkinson's disease-where do we stand?

Authors:  André Toulouse; Aideen M Sullivan
Journal:  Prog Neurobiol       Date:  2008-06-05       Impact factor: 11.685

4.  Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids.

Authors:  A J Berk; P A Sharp
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

5.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

6.  Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro.

Authors:  Gerard W O'Keeffe; Peter Dockery; Aideen M Sullivan
Journal:  J Neurocytol       Date:  2004-09

Review 7.  Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration.

Authors:  A Storch; A C Ludolph; J Schwarz
Journal:  J Neural Transm (Vienna)       Date:  2004-10       Impact factor: 3.575

8.  Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells.

Authors:  Catherine R McMillan; Rohita Sharma; Tom Ottenhof; Lennard P Niles
Journal:  Neurosci Lett       Date:  2007-04-19       Impact factor: 3.046

9.  Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Authors:  Christopher D Herzog; Biplob Dass; James E Holden; James Stansell; Mehdi Gasmi; Mark H Tuszynski; Raymond T Bartus; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

10.  Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration.

Authors:  A M Sullivan; J Opacka-Juffry; J Pohl; S B Blunt
Journal:  Brain Res       Date:  1999-02-06       Impact factor: 3.252

View more
  6 in total

1.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

2.  A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.

Authors:  Shane V Hegarty; Eimear O'Leary; Franziska Solger; Joanna Stanicka; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neurotox Res       Date:  2016-06-02       Impact factor: 3.911

3.  Human SNF2L gene is regulated constitutively and inducibly in neural cells via a cAMP-response element.

Authors:  Yu Xia; Laicheng Wang; Chunyan Ma; Yaoqin Gong; Yueran Zhao
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

Review 4.  Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.

Authors:  Gerard W O'Keeffe; Shane V Hegarty; Aideen M Sullivan
Journal:  Neuronal Signal       Date:  2017-03-31

5.  NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.

Authors:  Jayanth Anantha; Susan R Goulding; Eszter Tuboly; Adam G O'Mahony; Gerard M Moloney; Gareth Lomansey; Cathal M McCarthy; Louise M Collins; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2021-10-08       Impact factor: 5.682

6.  STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5.

Authors:  Jayanth Anantha; Susan R Goulding; Sean L Wyatt; Ruth M Concannon; Louise M Collins; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  iScience       Date:  2020-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.